Parkman Healthcare Partners LLC bought a new position in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 278,775 shares of the company's stock, valued at approximately $1,419,000. Parkman Healthcare Partners LLC owned about 0.94% of Eliem Therapeutics as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in ELYM. Ikarian Capital LLC boosted its position in shares of Eliem Therapeutics by 75.1% during the 3rd quarter. Ikarian Capital LLC now owns 175,100 shares of the company's stock valued at $891,000 after acquiring an additional 75,100 shares during the last quarter. Janus Henderson Group PLC boosted its position in shares of Eliem Therapeutics by 10.8% during the 3rd quarter. Janus Henderson Group PLC now owns 3,606,495 shares of the company's stock valued at $18,303,000 after acquiring an additional 352,507 shares during the last quarter. Ally Bridge Group NY LLC lifted its position in Eliem Therapeutics by 145.9% in the third quarter. Ally Bridge Group NY LLC now owns 1,229,292 shares of the company's stock valued at $6,257,000 after buying an additional 729,292 shares during the last quarter. MetLife Investment Management LLC acquired a new position in Eliem Therapeutics in the third quarter valued at about $90,000. Finally, Great Point Partners LLC acquired a new position in Eliem Therapeutics in the third quarter valued at about $1,263,000. Institutional investors and hedge funds own 69.76% of the company's stock.
Eliem Therapeutics Trading Down 3.4 %
NASDAQ ELYM traded down $0.11 during trading hours on Wednesday, reaching $3.15. The company had a trading volume of 141,145 shares, compared to its average volume of 486,688. The stock has a market capitalization of $93.72 million, a P/E ratio of -5.94 and a beta of -0.39. The stock has a 50-day moving average of $4.24 and a 200 day moving average of $6.31. Eliem Therapeutics, Inc. has a 1-year low of $2.35 and a 1-year high of $11.55.
About Eliem Therapeutics
(
Free Report)
Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Further Reading
Before you consider Eliem Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eliem Therapeutics wasn't on the list.
While Eliem Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
